8-K: EDAP TMS Reports Record Q1 HIFU Revenue Growth

EDAP TMS SA announced strong first quarter 2026 financial results, driven by a significant 78% year-over-year increase in High-Intensity Focused Ultrasound (HIFU) revenue, reaching $11.6 million.

Summary

• EDAP TMS SA reported its strongest first quarter for High-Intensity Focused Ultrasound (HIFU) revenue, which grew 78% year-over-year to $11.6 million.
• The company saw a 53% increase in U.S. Focal One procedures and an 83% rise in Focal One system shipments.
• Total worldwide revenue for Q1 2026 was $17.8 million, up from $14.3 million in Q1 2025.
• Gross profit margin improved to 45.7% from 42.0% due to a favorable product mix and increased HIFU revenue absorption.
• Operating expenses increased to $15.5 million from $12.3 million, leading to an operating loss of $7.4 million, compared to $6.3 million in the prior year.
• Net loss for the quarter was $9.1 million, or ($0.24) per share, an increase from the $7.4 million net loss ($0.20 per share) in Q1 2025.
• The company reiterated its 2026 revenue guidance, expecting HIFU business revenue between $50.0 million and $54.0 million (34%-45% growth).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth in its core HIFU business and positive clinical study results, despite an increased operating loss.

Positives

• Record first quarter HIFU revenue of $11.6 million, a 78% increase year-over-year.
• Seventh consecutive quarter of year-over-year HIFU revenue growth.
• 53% growth in U.S. Focal One procedures.
• 83% growth in First Quarter Focal One shipments.
• Gross profit margin increased to 45.7% from 42.0% due to favorable product mix and HIFU revenue growth.
• Secured international capital sales in the UK, France, and Hungary for Focal One Robotic HIFU systems.
• Landmark HIFI-2 study results published in European Urology Oncology showing promise for salvage HIFU treatment.

Negatives

• Operating expenses increased significantly to $15.5 million from $12.3 million.
• Operating loss widened to $7.4 million from $6.3 million.
• Net loss increased to $9.1 million ($0.24 per share) from $7.4 million ($0.20 per share).
• Total current assets decreased to $50.4 million from $57.2 million.
• Total shareholders equity decreased to $10.1 million from $19.4 million.
• Cash, cash equivalents and short-term investments decreased to $15.0 million from $20.5 million.
• Net cash used in operating activities was $3.0 million, compared to $5.3 million in the prior year period.

Risks

• The uncertain worldwide economic, political and financial environment.
• Geopolitical instability.
• Climate change and pandemics, or other public health crises, and their related impact on business operations.
• Risks associated with the clinical status and market acceptance of HIFU devices.
• Continued market potential for lithotripsy and distribution divisions.
• Worldwide inflationary environment.

Future Outlook

The company reiterates its 2026 revenue guidance, expecting core HIFU business revenue to be between $50.0 million and $54.0 million, representing 34% to 45% year-over-year growth. Revenue for the combined non-core ESWL and Distribution business is expected to be between $22.0 million and $26.0 million.

Management Comments

• "We delivered our strongest HIFU quarter to date, with revenue of $11.6 million, representing 78% year over year growth."
• "U.S. Focal One procedure volumes reached a record high for the company with 53% year over year growth."
• "We are executing well against our 2026 priorities and our results reflect a growing HIFU business."
• "This includes expanded capital sales in key markets along with notable increased utilization across our global installed base."
• "The publication of the HIFI-2 study further reinforces Focal Ones unique position as a non-invasive, organ-sparing, and function-preserving treatment option for a patient population that has historically faced limited therapeutic alternatives beyond palliative care."

Industry Context

StockSavvy.ai notes that EDAP TMS's strong HIFU revenue growth aligns with a broader trend in the medical device industry towards minimally invasive and robotic-assisted surgical solutions, particularly in urology. The company's focus on prostate cancer and endometriosis treatments positions it within growing market segments.

Comparison to Industry Standards

• The 78% year-over-year growth in HIFU revenue significantly outpaces the typical growth rates seen in established medical device segments, suggesting strong market adoption for EDAP's technology.
• The 83% increase in Focal One system shipments indicates a successful expansion of the company's installed base, a key driver for recurring revenue from disposables and services, which is a common strategy for medical device companies like Intuitive Surgical (ISRG) with its da Vinci systems.
• The reported gross profit margin of 45.7% is competitive within the specialized medical device sector, though specific benchmarks vary widely by product complexity and market maturity.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to strong revenue growth in the core HIFU business, though offset by widening net loss.
• Patients: Access to potentially improved treatment options for prostate cancer and endometriosis through the Focal One HIFU platform.
• Healthcare Providers: Continued adoption of advanced robotic HIFU technology for patient care.

Next Steps

• Present at the American Urological Association (AUA) Annual Meeting (May 15-18).
• Host Investor Day at Nasdaq MarketSite (June 1).
• Present at the Jefferies Global Healthcare Conference (June 4).

Key Dates

Recommendation

While the revenue growth and HIFU performance are very strong, the increasing operating loss and net loss, coupled with a decrease in cash reserves, warrant a cautious approach. The company is executing well on its growth strategy, but profitability remains a concern. Investors should monitor the path to profitability and continued market adoption.

Keywords

EDAP TMS, HIFU, Focal One, Prostate Cancer Treatment, Robotic Surgery, Medical Devices, Financial Results, Q1 2026